CXCL13 and in situ carcinoma: CSF concentrations of CXCL13 decreased after therapy with autologous hematopoietic stem cell transplant (AHSCT) in patients with RRMS at the first follow-up at 1 year than at baseline (Lundblad et al., 2023), and after therapy with rituximab, natalizumab and high-dose methylprednisolone in patients with CIS, RRMS, PPMS and SPMS (Serafini et al., 2004; Irani, 2016; Sellebjerg et al., 2009).